Resource Type

Journal Article 1

Year

2023 1

Keywords

RET-alteration 1

drug resistance 1

lung cancer 1

pralsetinib 1

selpercatinib 1

thyroid cancer 1

tumor-agnostic therapy 1

open ︾

Search scope:

排序： Display mode:

Progress and challenges in RET-targeted cancer therapy

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 207-219 doi: 10.1007/s11684-023-0985-y

Abstract: , two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinibAlthough pralsetinib and selpercatinib gave high overall response rates (ORRs), < 10%selpercatinibSeveral next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET

Keywords： pralsetinib     selpercatinib     RET-alteration     lung cancer     thyroid cancer     tumor-agnostic therapy     drug    

HTML PDF Collect

Title Author Date Type Operation

Progress and challenges in RET-targeted cancer therapy

Journal Article